Alzamend Neuro Inc (NASDAQ:ALZN) shares, rose in value on Thursday, April 16, with the stock price down by -5.63% to the previous day’s close as strong demand from buyers drove the stock to $0.67.
Actively observing the price movement in the last trading, the stock closed the session at $0.71, falling within a range of $0.6667 and $0.7263. The value of beta (5-year monthly) was -0.192. Referring to stock’s 52-week performance, its high was $15.06, and the low was $0.64. On the whole, ALZN has fluctuated by -29.53% over the past month.
With the market capitalization of Alzamend Neuro Inc currently standing at about $4.43 million, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-Mar-09.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that ALZN’s technical picture suggests that short-term indicators denote the stock is a 50% Sell on average. However, medium-term indicators have put the stock in the category of 100% Sell while long-term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the price of ALZN currently trading nearly -26.60% and -26.04% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 30.88, while the 7-day volatility ratio is showing 9.86% which for the 30-day chart, stands at 10.27%. Furthermore, Alzamend Neuro Inc (ALZN)’s beta value is -0.11, and its average true range (ATR) is 0.09.
A comparison of Alzamend Neuro Inc (ALZN) with its peers suggests the former has fared considerably weaker in the market. ALZN showed an intraday change of -5.63% in last session, and over the past year, it shrunk by -91.21%%.
Data on historical trading for Alzamend Neuro Inc (NASDAQ:ALZN) indicates that the trading volumes over the past 10 days have averaged 0.13 and over the past 3 months, they’ve averaged 379.46K. According to company’s latest data on outstanding shares, there are 6.61 million shares outstanding.
Nearly 4.42% of Alzamend Neuro Inc’s shares belong to company insiders and institutional investors own 1.71% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 0.36 million shares as on 2025-03-31, resulting in a short ratio of 1.75. According to the data, the short interest in Alzamend Neuro Inc (ALZN) stood at 561.00 of shares outstanding as of 2025-03-31; the number of short shares registered in 2025-02-28 reached 0.23 million. The stock has fallen by -42.24% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the ALZN stock heading into the next quarter.
